Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00646035 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

A Phase 3 study of End Stage Renal Disease, sponsored by Abbott.

Completed
Registry status
Phase 3
Development phase
75
Enrollment target
20
Study locations

NCT00646035 is a Phase 3 study of End Stage Renal Disease that has completed, run by Abbott. The registered enrollment target is 75 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00646035, a Phase 3 study of End Stage Renal Disease, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 3
Development phase
75 participants
Enrollment target
20
Study locations

Study Summary

To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.

Conditions Studied

End Stage Renal Disease

Interventions

  • DRUG paricalcitol capsules

Study Locations (20)

Ohio

  • - Cincinnati
  • - Cincinnati
  • - Cleveland

Florida

  • - Fort Myers
  • - Tampa

Illinois

  • - Evanston
  • - Maywood

Tennessee

  • - Memphis
  • - Nashville

California

  • - Los Angeles

Colorado

  • - Denver

District of Columbia

  • - Washington D.C.

Georgia

  • - Savannah

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2002-01
Phase Phase 3

Sponsor

Abbott

181 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00646035

The ClinicalTrials.gov registry entry for NCT00646035 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (91% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which paricalcitol capsules is the first listed.

NCT00646035 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ohio, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT00646035 about?

NCT00646035 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis". To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.

What is the current status of trial NCT00646035?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2002-01.

What conditions does trial NCT00646035 study?

This clinical trial studies the following conditions: End Stage Renal Disease.

What interventions are being tested in trial NCT00646035?

The interventions under investigation include: paricalcitol capsules (DRUG).

Who is sponsoring clinical trial NCT00646035?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00646035 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

End Stage Renal Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.